Clinical data | |
---|---|
Trade names | Glurenorm |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral (tablets) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High (Tmax = 2–3 hours) |
Metabolism | Extensive hepatic |
Onset of action | 1–1.5 hours |
Excretion | Biliary (95%), renal (5%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.046.770 |
Chemical and physical data | |
Formula | C27H33N3O6S |
Molar mass | 527.64 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class.[1] It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).